Trademark: 85902409
Word
NABOTA
Status
Dead
Status Code
711
Status Date
Thursday, January 14, 2021
Serial Number
85902409
Registration Number
4535957
Registration Date
Tuesday, May 27, 2014
Mark Type
4000
Filing Date
Friday, April 12, 2013
Published for Opposition
Tuesday, March 11, 2014
Cancellation Date
Thursday, January 14, 2021

Trademark Owner History
DAEWOONG PHARMACEUTICAL CO., LTD. - Original Registrant

Classifications
5 Botulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; Pharmaceutical preparations, namely, acne medications, acne treatment preparations, adrenal hormone preparations, alcohol for topical use, allergy and allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, bactericides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretics, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, chemical compounds for drug delivery, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, vaccine adjuvants, vaccine stabilizers, diuretics, amino acids for medical purposes; Medicines for the treatment of gastrointestinal diseases; chemical preparations for pharmaceutical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; chemico-pharmaceutical preparations for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; drugs for medical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; Medicines for human purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; pharmaceutical preparations for activating cellular function; Adjuvants for medical purposes; pharmaceutical preparations for central nerve treatment; pharmaceutical preparations for diagnosis; dermatological pharmaceutical products; pharmaceutical preparations for treating skin disorders; antibiotic preparations; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for chemical disorder treatment
Color is not claimed as a feature of the mark.

Trademark Events
Jan 15, 2021
Notice Of Cancellation Sec. 7 Surrender Emailed
Jan 14, 2021
Cancelled Section 7-Total
Oct 19, 2020
Request For Sect 7 Total Surrender Filed
Jan 8, 2021
Case Assigned To Post Registration Paralegal
Oct 19, 2020
Teas Section 7 Surrender Received
Oct 19, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 19, 2020
Teas Change Of Correspondence Received
Oct 19, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 19, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 19, 2020
Teas Change Of Owner Address Received
May 27, 2019
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
May 27, 2014
Registered-Principal Register
Mar 11, 2014
Official Gazette Publication Confirmation E-Mailed
Mar 11, 2014
Published For Opposition
Feb 19, 2014
Notification Of Notice Of Publication E-Mailed
Feb 4, 2014
Law Office Publication Review Completed
Jan 29, 2014
Approved For Pub - Principal Register
Jan 28, 2014
Teas/Email Correspondence Entered
Jan 28, 2014
Correspondence Received In Law Office
Jan 21, 2014
Assigned To Lie
Dec 30, 2013
Teas Response To Office Action Received
Jul 30, 2013
Notification Of Non-Final Action E-Mailed
Jul 30, 2013
Non-Final Action E-Mailed
Jul 30, 2013
Non-Final Action Written
Jul 29, 2013
Assigned To Examiner
Apr 18, 2013
New Application Office Supplied Data Entered In Tram
Apr 16, 2013
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24